Tags

Type your tag names separated by a space and hit enter

[Cutaneous leishmaniasis treated with ambisome (liposomal amphotericin B)].
Harefuah. 2012 Aug; 151(8):458-60, 498.H

Abstract

Cutaneous leishmaniasis, caused mainly by Leishmania major, is endemic in southern Israel. It is characterized by multiple skin lesions on the skin's patient. The treatment often includes only topical treatment, and treatment failures are not uncommon. Liposomal amphotericin B, a drug approved for visceral leishmaniasis treatment, has rarely been used for the cutaneous disease, especially for Old World cutaneous leishmaniasis. We report a 1-year-old patient with multiple skin Lesions, diagnosed as leishmania major infection. The patient's parents refused topical treatment, as they were concerned regarding the possibility of treatment failure and residual facial scars. The patient was treated with intravenous liposomal amphotericin B, given as a 6 dose regimen and was cured clinically without any complications. Post-treatment evaluation, including direct microscopy, culture and polymerase chain reaction (PCR) revealed no evidence of residual disease. We believe that liposomal amphotericin B, although expensive, should be considered for cutaneous leishmaniasis treatment, when systemic treatment is needed, such as in cases with multiple facial skin lesions.

Authors+Show Affiliations

Pediatric infectious Disease Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. shalomb2@clalit.org.ilNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

heb

PubMed ID

23350289

Citation

Ben-Shimol, Shalom, et al. "[Cutaneous Leishmaniasis Treated With Ambisome (liposomal Amphotericin B)]." Harefuah, vol. 151, no. 8, 2012, pp. 458-60, 498.
Ben-Shimol S, Sagi O, Schwartz E, et al. [Cutaneous leishmaniasis treated with ambisome (liposomal amphotericin B)]. Harefuah. 2012;151(8):458-60, 498.
Ben-Shimol, S., Sagi, O., Schwartz, E., & Greenberg, D. (2012). [Cutaneous leishmaniasis treated with ambisome (liposomal amphotericin B)]. Harefuah, 151(8), 458-60, 498.
Ben-Shimol S, et al. [Cutaneous Leishmaniasis Treated With Ambisome (liposomal Amphotericin B)]. Harefuah. 2012;151(8):458-60, 498. PubMed PMID: 23350289.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cutaneous leishmaniasis treated with ambisome (liposomal amphotericin B)]. AU - Ben-Shimol,Shalom, AU - Sagi,Orli, AU - Schwartz,Eli, AU - Greenberg,David, PY - 2013/1/29/entrez PY - 2013/1/29/pubmed PY - 2013/2/16/medline SP - 458-60, 498 JF - Harefuah JO - Harefuah VL - 151 IS - 8 N2 - Cutaneous leishmaniasis, caused mainly by Leishmania major, is endemic in southern Israel. It is characterized by multiple skin lesions on the skin's patient. The treatment often includes only topical treatment, and treatment failures are not uncommon. Liposomal amphotericin B, a drug approved for visceral leishmaniasis treatment, has rarely been used for the cutaneous disease, especially for Old World cutaneous leishmaniasis. We report a 1-year-old patient with multiple skin Lesions, diagnosed as leishmania major infection. The patient's parents refused topical treatment, as they were concerned regarding the possibility of treatment failure and residual facial scars. The patient was treated with intravenous liposomal amphotericin B, given as a 6 dose regimen and was cured clinically without any complications. Post-treatment evaluation, including direct microscopy, culture and polymerase chain reaction (PCR) revealed no evidence of residual disease. We believe that liposomal amphotericin B, although expensive, should be considered for cutaneous leishmaniasis treatment, when systemic treatment is needed, such as in cases with multiple facial skin lesions. SN - 0017-7768 UR - https://www.unboundmedicine.com/medline/citation/23350289/[Cutaneous_leishmaniasis_treated_with_ambisome__liposomal_amphotericin_B_]_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -